American Board Of Preventive Medicine

Featured Activities

• Opioid Use Disorder Education Program - Course 1: Understanding Addiction Harvard Medical School

  This course is one of three that comprise the Opioid Use Disorder Education Program (OUDEP), an innovative continuing medical education program produced by Harvard Medical School (HMS). This course is intended for nurses, nurse practitioners, physician assistants, physicians, social workers, and other health care providers collaborating to treat patients with substance use disorders. Understanding Addiction focuses on the fundamentals regarding the nature of addiction including: the epidemiology of opioid use disorder, the chronic nature of OUD, the differences between dependence and use disorders, and the neurobiology behind addiction. This course also focuses on the changing perceptions and current stigmas surrounding opioid use disorder.

  Learner must complete all 8 credits to acquire CME. 

  View Activity

• Moving Beyond the Barriers of Treating Opioid Use Disorder American Society of Addiction Medicine

  Providers often receive their waiver but never move on to treat patients. This case-based interactive 2.5-hour course addresses moving beyond common barriers that prevent DEA-waivered clinicians from successfully treating patients with OUD. Common barriers related to implementing office-based treatment and patient care will be discussed, as well as how to address these barriers such as regulation, legislation, and stigma.

  View Activity

• Using AMNet to Track Opioid Use Disorder Treatment Outcomes American Society of Addiction Medicine

  The activity will help learners to apply assessment tools from the AMNet platform to track OUD treatment outcomes. It will also provide an overview of The ASAM National Practice Guideline for the Treatment of Opioid Use Disorder – 2020 Focused Update. The focused update includes new and revised recommendations based on new science/research/literature in the field, and new products/formulations that have emerged. This is especially critical in the context of COVID-19, during which regulations for medication induction and delivery have changed.

  View Activity